China SXT Pharmaceuticals launches $9M registered direct offering

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced a registered direct offering of 4,500,000 units at $2.00 per unit, with expected gross proceeds of approximately $9 million before placement agent fees and other expenses.

Each unit consists of one Class A ordinary share and one warrant with an exercise price of $3.20 per share. The warrants are immediately exercisable upon issuance and expire one year from the date of issuance.

The offering is being made pursuant to a shelf registration statement on Form F-3 previously filed with the U.S. Securities and Exchange Commission, which became effective on December 1, 2025. Univest Securities, LLC is acting as the sole placement agent.

The transaction is expected to close on or about July 24, 2025, subject to customary closing conditions. The company is headquartered in Taizhou City, Jiangsu Province, China, and focuses on the manufacture and sale of traditional Chinese medicine products.

You May Also Be Interested In

• ESS Tech launches $3.2M stock offering at $0.50 per share
• Ocean Power Technologies regains NYSE compliance after late 10-K filing
• QTREX Quantum prices $10 million registered direct offering